http://www.FranchiUSA.com/franchi-48al-shotgun/The legendary 48-AL shotgun has stood the test of time and continues to impress hunters and shooters alike. Th...
Manufacturer: Franchi Model: 48 AL Field SKU: 40205 Action: Semi-Auto Caliber: 20 Gauge, 2.75" Capacity: 4 + 1 Rounds Barrel Length: 26" Vent Rib Overall Length: 46" Chokes: IC, M, F, and Wrench Stock: Satin Walnut Sights: Bead Length of Pull: 14.25" Weight: 5.6 lbs This Franchi is the Model 48 AL Field.
Découvrez tous nos produits. Téléchargez nos catalogues. Catalogue des publications
They still make the 48 AL, so they must still make the parts. I have several older Franchi 48 ALs in 12 gauge, which as you probably know, aren't manufactured anymore. Two were missing the correct friction ring and friction spring and parts are scarce.
I was recently looking at the franchi website and noticed that the al-48 was no longer on there. Is it because they discontinued it or am I just missing it? Search " " across the entire site Search " " in this forum Search " " in this discussion
Updated from Llovet et al. , according to IARC data . AAIR, age-adjusted incidence rate. 912. fraction is due to hepatitis B (60%) whereas in the developed Western world, only 20% of cases can be attributed to HBV infection, while chronic hepatitis C appears to be the major risk factor .
48 AL The Traditional Featherweight. 48 AL DELUXE 28-GA, 2" ITEM # 40217 A-Grade satin walnut, polished blue. With a featherweight, yet durable, aluminum receiver, the Franchi 48 AL upland field gun represents the ultimate refinement of long-recoil auto-loaders.
Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S911/C9190. J Clin Oncol. 2000;18(12):2444-2458. Cameron DA, Cornbleet MC, Mackie RM, et al. Adjuvant interferon alpha 2b in high risk melanoma-the Scottish study.
Mahan CE, Borrego ME, Woersching AL, et al. Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates. Thromb Haemost 2012; 108(2): 291-302.